Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.42 |
| ▸ | AS3MT | Q9HBK9 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10096453 | 0.98 | MEN1 (0.40) | NSD2DOT1LAS3MTALDH1A1TP53 | |
| SCHEMBL12105433 | 0.94 | ALDH1A1 (0.50) | NSD2DOT1LAS3MTALDH1A1TP53 | |
| SCHEMBL12105764 | 0.93 | AS3MT (0.49) | NSD2DOT1LAS3MTALDH1A1TP53 | |
| SCHEMBL10096275 | 0.92 | NSD2 (0.43) | NSD2DOT1LAS3MTALDH1A1MEN1 | |
| SCHEMBL12106612 | 0.91 | NSD2 (0.41) | NSD2DOT1LAS3MTTP53PDE1C | |
| SCHEMBL10096424 | 0.90 | NSD2 (0.43) | NSD2DOT1LAS3MTALDH1A1TP53 | |
| SCHEMBL10096476 | 0.89 | NPC1 (0.53) | NSD2DOT1LAS3MTTP53MEN1 | |
| SCHEMBL10096436 | 0.89 | NSD2 (0.42) | NSD2DOT1LAS3MTALDH1A1TP53 | |
| SCHEMBL10096440 | 0.89 | HPGD (0.42) | NSD2DOT1LAS3MTALDH1A1TP53 | |
| SCHEMBL10097620 | 0.88 | ALDH1A1 (0.43) | NSD2DOT1LAS3MTALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7781478-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781478-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | NSD2 3927/4885DOT1L 4064/4885AS3MT 2763/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | NSD2 3223/4885DOT1L 3677/4885AS3MT 2625/4885 |
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | NSD2 3223/4885DOT1L 3677/4885AS3MT 2625/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | NSD2 3529/4885DOT1L 4480/4885AS3MT 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.